Sign in to view content

Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting

Matthew Starr, MD

Video
Published 2021

Related

Comparability of Diabetic Retinopathy Severity Evaluation on Gold Standard vs Ultra-Widefield Images in YOSEMITE/RHINE Phase 3 Studies
Barbara A. Blodi, MD
Annual Meeting Talks
2025
Benefits and Value of Treatment for Diabetic Macular Edema
Paul Hahn, MD, PhD, FASRS
Updates from the Field
2022
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD, FASRS
Updates from the Field
2021

Category: Diabetic Retinopathy

See more